4//SEC Filing
Mitola John P 4
Accession 0001144204-13-001665
CIK 0001419583other
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 1:22 PM ET
Size
15.0 KB
Accession
0001144204-13-001665
Insider Transaction Report
Form 4
Cellteck Inc.CLTK
Mitola John P
DirectorCorporate Secretary
Transactions
- Conversion
Options to acquire Series B convertible preferred stock
2012-12-31−50,000→ 0 total(indirect: By LLC)From: 2012-12-31→ Common Stock (40,000,000 underlying) - Conversion
Series B convertible preferred stock
2012-12-31+50,000→ 500,000 total(indirect: By LLC)→ Common Stock (40,000,000 underlying)
Holdings
- 100,000(indirect: By LLC)
Options to acquire Series B convertible preferred stock
→ Common Stock (80,000,000 underlying) - 25,000
Options to purchase Series B convertible preferred stock
Exercise: $2.50From: 2012-05-01Exp: 2015-05-01→ Common Stock (20,000,000 underlying) - 50,000(indirect: By LLC)
Series B convertible preferred stock
→ Common Stock (40,000,000 underlying)
Footnotes (6)
- [F1]On July 1, 2012, Quantum Advisors, LLC ("Quantum"), of which Mr. Mitola is the managing member, entered into a Services Agreement with Eos Petro, Inc. ("Eos") in order to provide consulting services to Eos, pursuant to which Quantum was granted options to acquire 200,000 shares of common stock of Eos. Such options were converted into options to acquire 200,000 shares of Series B convertible preferred stock of Cellteck, Inc. ("Cellteck") in connection with the merger of Eos and Cellteck. The options do not have an exercise price or expiration date. Instead, 50,000 options vest automatically and convert into shares of Series B convertible preferred stock on each of the following dates: July 1, 2012; December 31, 2012; July 1, 2013; and December 31, 2013, provided that the Services Agreement is still in effect as of each such date. If the Services Agreement is terminated, any options that have not yet vested by that date will expire.
- [F2]Consists of options to acquire 50,000 shares of Series B convertible preferred stock which automatically vested and converted on December 31, 2012 pursuant to the Services Agreement detailed in footnote 1 above.
- [F3]Consists of 50,000 shares of Series B convertible preferred stock issued upon the automatic conversion of the options reported in footnote 2 above. Each share of Series B convertible preferred stock is convertible into 800 shares of common stock, and Series B convertible preferred stock is automatically convertible upon the filing of a certain amendment to Cellteck's Articles of Incorporation. Series B convertible preferred stock has no exercise date, exercise price or expiration date.
- [F4]Consists of options to acquire 100,000 shares of Series B convertible preferred stock pursuant to the Services Agreement detailed above in footnote 1. Options to acquire 50,000 shares will automatically vest and convert on both July 1, 2013 and December 31, 2013, provided that the Services Agreement is still in effect as of each such date.
- [F5]Consists of 50,000 shares of Series B convertible preferred stock issued upon the automatic conversion of options to acquire 50,000 shares of Series B convertible preferred stock on July 1, 2012 pursuant to the Services Agreement detailed in footnote 1 above. Each share of Series B convertible preferred stock is convertible into 800 shares of common stock, and Series B convertible preferred stock is automatically convertible upon the filing of a certain amendment to Cellteck's Articles of Incorporation. Series B convertible preferred stock has no exercise date, exercise price or expiration date.
- [F6]Consists of options to purchase up to 25,000 shares of Series B convertible preferred stock. The options were originally granted to Mr. Mitola on May 1, 2012 as options to purchase up to 25,000 shares of common stock of Eos for Mr. Mitola's services as a non-employee director of Eos. Such options were converted into options to purchase up to 25,000 shares of Series B convertible preferred stock of Cellteck on October 12, 2012 in connection with the merger of Eos and Cellteck. The options vested immediately on the grant date, expire on May 1, 2015 and have an exercise price of $2.50.
Documents
Issuer
Cellteck Inc.
CIK 0001419583
Entity typeother
Related Parties
1- filerCIK 0001438470
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 1:22 PM ET
- Size
- 15.0 KB